|
|
|
| Efficacy and Prognostic Analysis of Erlotinib in Combination with Anlotinib or Bevacizumab Monoclonal Antibody in the Treatment of EGFR-sensitive Mutant Advanced NSCLC |
| LI Xia, LU Husheng, LIU Tan, et al |
| 901 Hospital of the Chinese People's Liberation Army Joint Security Force, Anhui Hefei 230031, China |
|
|
|
|
Abstract Objective: To explore the efficacy and prognosis of erlotinib in combination with anlotinib or bevacizumab monoclonal antibody in the treatment of epidermal growth factor receptor (EGFR)-sensitive mutant advanced non-small cell lung cancer (NSCLC). Methods: A retrospective analysis was conducted on 107 patients with EGFR-sensitive mutant advanced NSCLC from September 2019 to February 2021, divided into Group A (55 cases) and Group B (52 cases). Group A received erlotinib + anlotinib, while Group B received erlotinib + bevacizumab. Short-term efficacy was assessed after one treatment cycle. Tumor markers, adverse reactions, and a 2-year follow-up were observed. Results: The objective response rate in Groups A and B was 58.18% and 63.46%, respectively, and the disease control rate was 89.09% and 90.38%, with no significant difference between the two groups (P>0.05). The differences in serum CA125, CEA, TPA, TK1, SCC-Ag, and CYFRA21-1 before and after treatment were not statistically significant (P>0.05). There was no significant difference in the incidence of adverse reactions between Groups A and B (P>0.05). The median progression-free survival in Groups A and B was 17.3 months and 18.1 months, respectively, with no statistically significant difference between the two groups (P>0.05). Conclusion: The efficacy and safety of erlotinib in combination with anlotinib or bevacizumab monoclonal antibody in the treatment of EGFR-sensitive mutant advanced NSCLC are comparable.
|
|
|
|
|
|
[1] Lamb YN.Osimertinib:a review in previously untreated,EGFR mutation-positive,advanced NSCLC[J].Target Oncol,2021,16(5):687-695.
[2] 陈明镜,杨峤,许子寒,等.基于iRECIST标准的晚期NSCLC免疫治疗的真实世界研究[J].第三军医大学学报,2020,42(5):480-486.
[3] He J,Su C,Liang W,et al.Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR-mutant non-small-cell lung cancer (EVIDENCE):a randomised,open-label,phase 3 trial[J].Lancet Respir Med,2021,9(9):1021-1029.
[4] Jiang Z,Zhang J,Sun H,et al.Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations:A retrospective study[J].Thorac Cancer,2021,12(17):2369-2374.
[5] Sanchez JF.Adverse drug reactions[J].Med Clin (Barc),2022,159(8):385-387.
[6] Sun SJ,Han JD,Liu W,et al.Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer[J].World Clin Cases,2022,10(18):6069-6081.
[7] Chan SK,Choi HC,Lee VH.Overall survival benefits of first-line treatments for asian patients with advanced epidermal growth factor receptor-mutated NSCLC harboring exon 19 deletion:a systematic review and network meta-analysis[J].Cancers,2022,14(14):3362-3365.
[8] 任炳楠,薛朝军,李宵,等.4种治疗晚期非小细胞肺癌的抗血管生成药物Mini卫生技术评估[J].中国新药杂志,2021,30(21):2009-2016.
[9] 杨泽兴,王宏伟.贝伐珠单抗治疗脑转移瘤瘤周水肿的短期疗效观察[J].中华神经外科杂志,2020,36(8):837-840. |
|
|
|
2023, Vol. 29 
